Fusion Antibodies (LON:FAB) Trading Down 12% – Here’s What Happened

Fusion Antibodies plc (LON:FAB)’s stock price traded down 12% during mid-day trading on Friday . The stock traded as low as GBX 6.22 ($0.08) and last traded at GBX 6.25 ($0.08). 3,481,229 shares were traded during mid-day trading, an increase of 197% from the average session volume of 1,171,104 shares. The stock had previously closed at GBX 7.10 ($0.09).

Fusion Antibodies Price Performance

The firm’s 50-day moving average is GBX 4.56 and its 200-day moving average is GBX 3.80. The company has a quick ratio of 2.36, a current ratio of 3.87 and a debt-to-equity ratio of 2.40. The company has a market capitalization of £6.15 million, a PE ratio of -161.25 and a beta of 0.49.

Insider Transactions at Fusion Antibodies

In other Fusion Antibodies news, insider Adrian Kinkaid acquired 83,728 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was bought at an average price of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,227.09). Company insiders own 11.39% of the company’s stock.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.